Compare PHK & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PHK | EVMN |
|---|---|---|
| Founded | 2003 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 844.1M | 892.4M |
| IPO Year | N/A | N/A |
| Metric | PHK | EVMN |
|---|---|---|
| Price | $4.55 | $21.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $44.17 |
| AVG Volume (30 Days) | ★ 653.9K | 386.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 12.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.18 | $13.89 |
| 52 Week High | $5.04 | $33.20 |
| Indicator | PHK | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 16.78 | 41.26 |
| Support Level | N/A | $15.25 |
| Resistance Level | $4.91 | $23.08 |
| Average True Range (ATR) | 0.05 | 2.25 |
| MACD | -0.03 | -0.81 |
| Stochastic Oscillator | 10.98 | 5.32 |
PIMCO High Income Fund is a closed-end management investment company. The company's primary investment objective is to seek high current income. The secondary objective of the company is to seek capital appreciation.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.